Gonadorelin (GnRH) – 10MG

(10 customer reviews)

$78.00

FREE Shipping on $200+ orders
FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

QuantityDiscountPrice
5 - 85%$74.10
9 +10%$70.20
-
+
Size 10MG
Form Lyophilized powder
Purity 99%
Contents Gonadorelin

Scientific Overview of Gonadorelin (GnRH)

Gonadorelin, also known as gonadotropin-releasing hormone (GnRH), is a peptide that has been studied for its role in influencing the hypothalamic-pituitary-gonadal (HPG) axis. It may be involved in stimulating the release of certain pituitary hormones that contribute to reproductive processes.

Alternative Names: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin

Studies and Research Data

Investigations into Cancer Models

Research has suggested that Gonadorelin may interact with hormonal pathways relevant to cancer studies. In laboratory investigations of estrogen-sensitive models, exposure to Gonadorelin has been associated with reduced proliferation potential. Experimental approaches also describe fusions of GnRH structures with enzymes that may provide targeted interactions with tumor cells. Further studies in prostate cancer models indicate that hormonal regulation through GnRH analogs may influence growth patterns, though results appear mixed and context-dependent.

Explorations in Cognitive Decline Research

Scientific studies have considered whether elevated luteinizing hormone (LH) levels may correlate with the development of memory impairment and Alzheimer’s-associated pathology. Some investigations in animal models suggest that reducing LH through GnRH analogs could potentially mitigate such changes. Research continues to explore whether selective modulation of LH may provide insights into experimental approaches to dementia without broadly disrupting the entire hormonal axis.

Gonadorelin Studies in Reproductive Development

Laboratory investigations into cryptorchidism models have reported that intermittent exposure to Gonadorelin may assist in testicular descent and maturation processes. Results indicate potential responses in a portion of cases, though outcomes appear variable.

Research on Spermatogenesis

Experimental studies involving hypothalamic dysfunction models have examined whether Gonadorelin might help reinitiate spermatogenic processes. Intermittent exposure appeared to stimulate pituitary activity, with downstream hormone production potentially supporting testicular androgen synthesis. Some reports suggest that longer-term studies may show the possibility of restored spermatogenesis, though findings remain preliminary.

Gonadorelin Hormonal Recovery Research

Certain studies have examined Gonadorelin’s potential role in post-exposure recovery of the HPG axis after androgen introduction. Results suggest that Gonadorelin may temporarily elevate pituitary hormones and endogenous androgen levels. In some cases, these responses appeared to persist beyond the experimental timeframe, pointing to possible research interest in hormonal rebalancing.

Conclusion

Overall, Gonadorelin has been studied across a variety of research models, including those involving reproductive function, cancer biology, and neurodegenerative processes. Findings suggest possible roles in hormonal modulation and receptor interactions, though results are variable and context-dependent. Continued research may further clarify how Gonadorelin and related analogs influence these systems.

References

  1. Maleksabet A, Zarei Jaliani H, Asgari A, Ramezani A, Erfani N. Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells. Iran J Med Sci. 2021 Jul;46(4):281-290.
  2. Bowen RL, Butler T, Atwood CS. Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer’s Disease. J Clin Oncol. 2016 Aug 10;34(23):2800.
  3. Secreto G, Muti P, Sant M, Meneghini E, Krogh V. Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy. Endocr Relat Cancer. 2017 Nov;24(11):C21-C29.
  4. Burnham V, Sundby C, Laman-Maharg A, Thornton J. Luteinizing hormone acts at the hippocampus to dampen spatial memory. Horm Behav. 2017 Mar;89:55-63.
  5. Meethal SV, Smith MA, Bowen RL, Atwood CS. The gonadotropin connection in Alzheimer’s disease. Endocrine. 2005 Apr;26(3):317-26.
  6. Spicer DV, Pike MC. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr. 1994;(16):139-47.
  7. Muzzi G, Bartolotta E, Cherubini V, Lomiento D. Effetti del trattamento con LH-RH sintetico spray nasale nel criptorchidismo. La Pediatria medica e chirurgica. 1990;12(1):53–55.
  8. Rao CV. Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women. Reprod Sci. 2017 Mar;24(3):355-368.
  9. Zhang L, Cai K, Wang Y, Ji W, Cheng Z, Chen G, Liao Z. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis. Am J Mens Health. 2019;13(1):1557988318818280.
  10. Pace JN, Miller JL, Rose LI. GnRH agonists: gonadorelin, leuprolide and nafarelin. Am Fam Physician. 1991 Nov;44(5):1777-82.
  11. Blumenfeld Z, Makler A, Frisch L, Brandes JM. Induction of spermatogenesis in hypogonadotropic azoospermic men by intravenous pulsatile GnRH. Gynecol Endocrinol. 1988;2(2):151–164.
  12. Secreto G, Girombelli A, Krogh V. Androgen excess in breast cancer development. Endocr Relat Cancer. 2019 Feb;26(2):R81-R94.
  13. Labrie F. Combined blockade of testicular and locally made androgens in prostate cancer. J Steroid Biochem Mol Biol. 2015 Jan;145:144-56.
  14. Bhasin S, Yuan QX, Steiner BS, Swerdloff RS. Hormonal effects of GnRH agonist in men. J Clin Endocrinol Metab. 1987 Sep;65(3):568-74.
  15. Smith MA, Bowen RL, Nguyen RQ, Perry G, Atwood CS, Rimm AA. Putative GnRH Agonist Therapy and Dementia. J Alzheimers Dis. 2018;63(4):1269-1277.
  16. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol. 2005;7 Suppl 5:S3-S12.
  17. Vollaard ES, van Beek AP, Verburg FA, Roos A, Land JA. GnRH agonist treatment in postmenopausal women with hyperandrogenism. J Clin Endocrinol Metab. 2011 May;96(5):1197-201.
  18. Labrie F. GnRH agonists and combined androgen blockade in prostate cancer. Endocr Relat Cancer. 2014 Aug;21(4):R301-17.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.

Certificate of Analysis - Gonadorelin (GnRH)

High Performance Liquid Chromatography - Gonadorelin (GnRH)

Mass Spectrometry - Gonadorelin (GnRH)

10 reviews for Gonadorelin (GnRH) – 10MG

  1. MariahZ

    Great, thank you!!!!

  2. christina63

  3. jessica7323

  4. vial760x

  5. Jessica73

    Good overall wish they offered SARMS

  6. robin8236

    Five stars all the way I would gladly recommend

  7. mary_davis

  8. rgray

  9. peter61

  10. michelle_dorsey

Only logged in customers may leave a review.

0
    YOUR CART
    Your cart is emptyBack to STORE